Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00267-6
Teng Gao, Meng Jin, Rowalt Alibudbud, Sawitri Assanangkornchai, Yankun Sun, Lin Lu
No Abstract
没有抽象的
{"title":"Etomidate misuse: a digital era threat to youth and a call for anticipatory control","authors":"Teng Gao, Meng Jin, Rowalt Alibudbud, Sawitri Assanangkornchai, Yankun Sun, Lin Lu","doi":"10.1016/s2215-0366(25)00267-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00267-6","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"28 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00265-2
Sri Mahavir Agarwal, Nicolette Stogios, Margaret Hahn
No Abstract
没有抽象的
{"title":"Weight management in severe mental illness: bridging the gap between guidelines and primary care","authors":"Sri Mahavir Agarwal, Nicolette Stogios, Margaret Hahn","doi":"10.1016/s2215-0366(25)00265-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00265-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"21 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00264-0
Mark Weiser, Itai Pessach, Amitai Ziv
No Abstract
没有抽象的
{"title":"Running a psychiatric ward in times of war","authors":"Mark Weiser, Itai Pessach, Amitai Ziv","doi":"10.1016/s2215-0366(25)00264-0","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00264-0","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"29 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00270-6
Ahmed Alhaj
No Abstract
没有抽象的
{"title":"Psychiatric care in Gaza: prescribing amid systematic health care collapse","authors":"Ahmed Alhaj","doi":"10.1016/s2215-0366(25)00270-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00270-6","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"52 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00279-2
Ole Köhler-Forsberg, Oleguer Plana-Ripoll, Nina Friis Bak Fuglsang
No Abstract
没有抽象的
{"title":"Respiratory diseases in individuals with severe mental illness","authors":"Ole Köhler-Forsberg, Oleguer Plana-Ripoll, Nina Friis Bak Fuglsang","doi":"10.1016/s2215-0366(25)00279-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00279-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"40 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00261-5
Holly Christina Smith, Irene Petersen, Joseph F Hayes, Kelvin P Jordan, Magnus Boman, Sube Banerjee, Kate Walters, Claudia Cooper, Juan Carlos Bazo-Alvarez
Background
In the UK, it is recommended by the National Institute for Health and Care Excellence (NICE) that if antipsychotics are initiated in people living with dementia, treatment should be at the lowest dose for the shortest time possible (1–3 months). In this study, we aimed to investigate how dose and duration of antipsychotic medication adhere to UK clinical guidelines and explore treatment restart details in those who stop treatment.
Methods
We did a retrospective cohort study using longitudinal UK primary care data from the IQVIA Medical Research Database. We included people living with dementia aged 60–85 years who received their first antipsychotic prescription between Jan 1, 2000, and Dec 31, 2023. Individuals with any previous antipsychotic prescriptions in their records more than 1 year before a dementia diagnosis and those who had missing social deprivation information were excluded from the study. Duration of first and subsequent antipsychotic treatment episodes, medication dosage, and treatment discontinuation and reinitiation rates were investigated. Duration and discontinuation were defined by grouping consecutive prescriptions into treatment episodes using the waiting time distribution method (80% inter-arrival density, 59 days). Daily doses were derived from strength and frequency information and categorised as low or moderate or high based on established minimum effective dose equivalences. People with lived experience of dementia care contributed throughout this project, shaping the research question and advising on interpretation and dissemination strategies.
Findings
In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60–85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6–8·7), exceeding NICE guidelines of 1–3 months and 18·1% [95% CI 17·4–18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7–50·1] on low dose, 14·8% [13·9–15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8–15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment af
{"title":"Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines","authors":"Holly Christina Smith, Irene Petersen, Joseph F Hayes, Kelvin P Jordan, Magnus Boman, Sube Banerjee, Kate Walters, Claudia Cooper, Juan Carlos Bazo-Alvarez","doi":"10.1016/s2215-0366(25)00261-5","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00261-5","url":null,"abstract":"<h3>Background</h3>In the UK, it is recommended by the National Institute for Health and Care Excellence (NICE) that if antipsychotics are initiated in people living with dementia, treatment should be at the lowest dose for the shortest time possible (1–3 months). In this study, we aimed to investigate how dose and duration of antipsychotic medication adhere to UK clinical guidelines and explore treatment restart details in those who stop treatment.<h3>Methods</h3>We did a retrospective cohort study using longitudinal UK primary care data from the IQVIA Medical Research Database. We included people living with dementia aged 60–85 years who received their first antipsychotic prescription between Jan 1, 2000, and Dec 31, 2023. Individuals with any previous antipsychotic prescriptions in their records more than 1 year before a dementia diagnosis and those who had missing social deprivation information were excluded from the study. Duration of first and subsequent antipsychotic treatment episodes, medication dosage, and treatment discontinuation and reinitiation rates were investigated. Duration and discontinuation were defined by grouping consecutive prescriptions into treatment episodes using the waiting time distribution method (80% inter-arrival density, 59 days). Daily doses were derived from strength and frequency information and categorised as low or moderate or high based on established minimum effective dose equivalences. People with lived experience of dementia care contributed throughout this project, shaping the research question and advising on interpretation and dissemination strategies.<h3>Findings</h3>In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60–85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6–8·7), exceeding NICE guidelines of 1–3 months and 18·1% [95% CI 17·4–18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7–50·1] on low dose, 14·8% [13·9–15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8–15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment af","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"71 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-16DOI: 10.1016/s2215-0366(25)00262-7
David Laguna-Muñoz, María P Pata, Ana Jiménez-Peinado, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Christoph U Correll, Marco Solmi, Javier Caballero-Villarraso, María Isabel Alarcón-Laguna, Fernando Sarramea
<h3>Background</h3>People with severe mental illness have a 10–20 year reduced life-expectancy compared with the general population. Respiratory diseases are a main cause of this premature mortality, but no comprehensive meta-analysis of overall and respiratory cause-specific mortality risk in this population exists. We aimed to evaluate the mortality from specific respiratory diseases for people with pooled severe mental illnesses and specific diagnoses, alongside mortality for specific mental disorders.<h3>Methods</h3>For this large-scale random-effects meta-analysis, we searched PubMed, PsycINFO, Embase, Scopus, African Index Medicus, and LILACS from database inception to April 6, 2025, for prospective or retrospective cohort studies published in English. We included studies reporting on patients with schizophrenia spectrum disorder, bipolar disorder, major depressive disorder or depressive episodes, or mixed severe mental illness (defined as at least two among bipolar, depressive, and schizophrenia spectrum disorders). Publications had to include a control group from the general population and quantified reporting. We excluded cross-sectional studies, reviews, systematic reviews, and meta-analyses; studies that did not have respiratory-related mortality data; studies of clustered mixed groups that did not have at least 70% of the patient sample corresponding to our diagnoses, or studies in which the data were not suitable for meta-analysis. The primary outcome was adjusted risk ratio (RR) of overall respiratory disease-related mortality in people with severe mental illness (both pooled and for the specific severe mental disorders) versus the general population control group. Two authors extracted the data using a predetermined data extraction form. The information extracted included first author, country, setting (inpatient, outpatient, or both), data source, design of the study (prospective or retrospective), number of participants and their demographics (sex and mean age), specific severe mental illness and respiratory disease diagnosis, and the RR mortality of each respiratory disease. We assessed the risk of bias in each study using the Newcastle–Ottawa scale and heterogeneity was assessed with a multilevel random-effects meta regression. Individuals with lived experience of mental illness were not involved in the design, analysis, or dissemination of this study. The study was conducted in accordance with PRISMA and was registered with PROSPERO (CRD42024563552).<h3>Findings</h3>Our search identified 83 studies that met the eligibility criteria. We included 4 837 720 people with pooled severe mental illness (2 383 821 males [49·3%] and 2 453 899 females [50·7%]; mean age 57·7 years [SD 13·5]). Data on ethnicity or race were insufficiently reported to be included in our study. Our control group comprised 785 538 236 individuals from the general population (382 185 432 [48·7%] males and 403 352 804 [51·3%] females). 57 studies included peopl
{"title":"Mortality from respiratory diseases in individuals with severe mental illness: a large-scale systematic review and meta-analysis of pooled and specific diagnoses","authors":"David Laguna-Muñoz, María P Pata, Ana Jiménez-Peinado, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Christoph U Correll, Marco Solmi, Javier Caballero-Villarraso, María Isabel Alarcón-Laguna, Fernando Sarramea","doi":"10.1016/s2215-0366(25)00262-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00262-7","url":null,"abstract":"<h3>Background</h3>People with severe mental illness have a 10–20 year reduced life-expectancy compared with the general population. Respiratory diseases are a main cause of this premature mortality, but no comprehensive meta-analysis of overall and respiratory cause-specific mortality risk in this population exists. We aimed to evaluate the mortality from specific respiratory diseases for people with pooled severe mental illnesses and specific diagnoses, alongside mortality for specific mental disorders.<h3>Methods</h3>For this large-scale random-effects meta-analysis, we searched PubMed, PsycINFO, Embase, Scopus, African Index Medicus, and LILACS from database inception to April 6, 2025, for prospective or retrospective cohort studies published in English. We included studies reporting on patients with schizophrenia spectrum disorder, bipolar disorder, major depressive disorder or depressive episodes, or mixed severe mental illness (defined as at least two among bipolar, depressive, and schizophrenia spectrum disorders). Publications had to include a control group from the general population and quantified reporting. We excluded cross-sectional studies, reviews, systematic reviews, and meta-analyses; studies that did not have respiratory-related mortality data; studies of clustered mixed groups that did not have at least 70% of the patient sample corresponding to our diagnoses, or studies in which the data were not suitable for meta-analysis. The primary outcome was adjusted risk ratio (RR) of overall respiratory disease-related mortality in people with severe mental illness (both pooled and for the specific severe mental disorders) versus the general population control group. Two authors extracted the data using a predetermined data extraction form. The information extracted included first author, country, setting (inpatient, outpatient, or both), data source, design of the study (prospective or retrospective), number of participants and their demographics (sex and mean age), specific severe mental illness and respiratory disease diagnosis, and the RR mortality of each respiratory disease. We assessed the risk of bias in each study using the Newcastle–Ottawa scale and heterogeneity was assessed with a multilevel random-effects meta regression. Individuals with lived experience of mental illness were not involved in the design, analysis, or dissemination of this study. The study was conducted in accordance with PRISMA and was registered with PROSPERO (CRD42024563552).<h3>Findings</h3>Our search identified 83 studies that met the eligibility criteria. We included 4 837 720 people with pooled severe mental illness (2 383 821 males [49·3%] and 2 453 899 females [50·7%]; mean age 57·7 years [SD 13·5]). Data on ethnicity or race were insufficiently reported to be included in our study. Our control group comprised 785 538 236 individuals from the general population (382 185 432 [48·7%] males and 403 352 804 [51·3%] females). 57 studies included peopl","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"21 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-09DOI: 10.1016/s2215-0366(25)00269-x
Tony Rousmaniere, Simon B Goldberg, John Torous
No Abstract
没有抽象的
{"title":"Large language models as mental health providers","authors":"Tony Rousmaniere, Simon B Goldberg, John Torous","doi":"10.1016/s2215-0366(25)00269-x","DOIUrl":"https://doi.org/10.1016/s2215-0366(25)00269-x","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"34 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}